Aim: To assess the association between baseline clinical prognostic factors and subsequent Disease Activity Score of 28 joints (DAS28) remission in early rheumatoid arthritis (RA).
INTRODUCTION
Current European League Against Rheumatism (EULAR), and American College of Rheumatology (ACR) treatment recommendations suggest differential management of rheumatoid arthritis (RA) on the basis of prognostic factors.
1,2 These factors include the presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA), burden of inflammatory disease and imaging.
2 While these factors permit guideline strategies for management, it is recognized that none alone or in combination provide sufficient evidence to allow efficient stratification of therapy in atrisk groups, especially in a general RA population. [3] [4] [5] Improved matrix predictive risk models are being developed, 6 -8 but the lack of reliable indicators limits the clinicians' abilities to accurately target patients requiring more aggressive early therapy.
We designed the PREDICT study to identify at-risk groups that may benefit from more frequent monitoring and adjustment of therapy or may benefit from early biologic intervention. We used real-world evidence from the Optimising Patient outcomes in Australian rhuematoLogy (OPAL) registry. [9] [10] [11] The OPAL quality use of medicines initiative (QUMI) is a pointof-care observational registry database of patients with RA that provides real-world data from clinical practice.
MATERIALS AND METHODS

Study design
The PREDICT study was a multi-center, longitudinal, observational study of patients with recently diagnosed RA. Patients were followed for up to 24 months. The primary objective of the study was to assess the association between Disease Activity Score (DAS) remission (as measured by the DAS of 28 joints -erythrocyte sedimentation rate [DAS28-ESR]) and baseline prognostic factors in early RA (i.e., newly presenting patients with RA whose date of clinical onset was < 12 months from their initial presentation at the clinic). Clinical prognostic factors were selected by an expert panel of experienced rheumatologists and refined to include factors that were easily obtainable during a clinic consultation. They included sex, autoantibody status, smoking, alcohol consumption, pattern of joint involvement, time from onset of symptoms to presentation, disease activity at presentation and time to first disease-modifying anti-rheumatic drug (DMARD). The study was approved by the University of New South Wales Human Research Ethics Committee (HREC 11163).
Participants
The OPAL QUMI is a point-of-care observational registry database of patients with RA.
9-11 It captures patient-and disease-specific information collected during routine consultations. The database is available for research purposes following appropriate ethics approval for each specific research question.
For the PREDICT study, eligible patients included all newly presented patients with RA whose date of clinical onset was < 12-24 months from their initial presentation at the clinic, were 18 years of age or older, were being treated at an OPAL QUMI participating clinic, had at least 6 months of follow-up data, and had a DAS28-ESR recorded in the time up to 24 months from the date of first consultation with the treating rheumatologist for RA. Patients who requested their data not to be collected for research purposes, and those patients whose initial RA diagnosis was subsequently changed to another diagnosis were excluded. 
Data sources and variables
Statistical methods
Data are summarized descriptively. The association between baseline prognostic factors, treatments and DAS28-ESR remission, at 12-24 months after the first visit, were assessed with univariate and multivariate logistic regression. Baseline prognostic factors included age, sex, DAS28-ESR score at baseline, joint pattern, onset pattern, smoking, alcohol frequency, weight, RF status and ACPA status. The multivariate model was built by including age and sex (as these variables had no missing values) along with one of the other potential prognostic factors. This approach was chosen to maximize the number of observations included in the multivariate model, which ranged from 242 with weight as the third covariate to 723 with RF status as the third covariate.
Analyses were conducted using TIBCO Spotfire S+ version 8.1 for Windows (TIBCO Software in., California, USA).
RESULTS
Patients
Of the 18 024 patients with RA in the OPAL QUMI database, 1017 satisfied the inclusion criteria and were included (Fig. 1) . As this was an observational study which collected data from routine clinical practices, there are a number of variables with missing data. The numbers of missing values for each parameter of interest are reported in Table 1 . Demographics and disease characteristics of the included patients are reported in Table 1 . The majority of patients were female (70%). Over half of the patients were both RF and ACPA positive at baseline. At baseline, there were 16.2% patients in remission. Of these, 13.3% remained in remission at 12-24 months. A further 41.5% of patients achieved remission during the 12-to 24-month follow-up period.
Univariate analysis
The odds of being in remission at 12-24 months were significantly higher in those who were in remission at baseline, and those who were abstinent from alcohol ( Table 2 ). The odds of being in remission at 12-24 months were reduced in those with intermittent migratory arthritis compared to polyarticular arthritis, although the proportions of patients with intermittent migratory arthritis and monoarticular arthritis are small compared to those with polyarticular arthritis (Table 2) .
There was a borderline interaction between sex and age (v 2 = 3.57, degrees of freedom [df] = 1, P = 0.059), with the odds of remission decreasing with increasing age in male patients, but remaining relatively stable in female patients (Fig. 2) .
Multivariate analysis
Results of the multivariate analysis are shown in Table 2 . Most odds ratios changed very little between the univariate and multivariate analyses, supporting the reliability of the findings. Baseline factors associated with significantly increased odds of remission included being in remission at baseline, being male, abstaining from alcohol and lower weight.
Patients needing more aggressive therapy
Based upon our modeling, some patients are likely to require more intensive treatment to achieve remission. These include female patients, those who are not in remission at baseline, those who consume alcohol daily, moderately or heavily, and those who are heavier in weight (Fig. 3) .
DISCUSSION
Results from this real-world data study suggest that sex, alcohol use and weight, along with being in Figure 1 Included participants. Note, excluded participants may have violated more than one inclusion criteria. remission at baseline, are important factors in determining whether a patient will be in remission 12-24 months after initial presentation. However, it is of interest that smoking, RF and ACPA status did not appear to have an influence on the odds of achieving remission in this cohort of patients, as has previously been reported, including in the EULAR guidelines.
2,12
Published guidelines recommend that treatment is based upon prognostic markers that are believed to predict treatment outcomes.
2 Documented poor prognostic factors include the presence of RF or ACPA, high disease activity (measured using disease activity indexes such as the DAS28) and early occurrence of erosions. While the presence of RF and cyclic citrullinated peptide (CCP) antibody have been widely suggested to be prognostic, [16] [17] [18] [19] the specificity of the immunoglobulins used to assess them are variable. 17 Furthermore, the baseline positivity or negativity does not appear as important as the titre of the antibody prior to treatment in predicting clinical response, at least for RF. 17 Pretreatment levels of CCP antibody do not seem to be associated with response, 17 and the conversion rate of RF in early arthritis appears to be less than in established RA, suggesting there may be differential effects at various time points of the disease. Importantly, other studies of remission in RA have not reported significant odds ratios associated with either of these factors. 20 A more aggressive treatment strategy adopted by clinicians in patients with positive serology could also explain the lack of association with disease activity in this study. High disease activity, identified by baseline DAS28 measures, has been established as a good predictor of remission, 13, 21 especially the C-reactive protein (CRP) 16, 20 or ESR 13 components. This is consistent with our data, and is reassuring.
2,13-15
By the time erosions have occurred in RA, the disease is already well established; therefore, we suggest that joint involvement is not a useful prognostic factor in modern treatment. Our study did not specifically look at different imaging modalities; however, the value of different forms of imaging has been reported to be useful in predicting development of RA from undifferentiated peripheral arthritis. 22 Magnetic resonance imaging and power Doppler ultrasound are increasingly being used to detect inflammation and bone injury, and allow management of RA before progression becomes detectable on X-ray. [23] [24] [25] They may also have prognostic value in aggressive disease, 23 but at this stage their predictive utility value is modest at best, and their lack of availability means their applicability in clinical practice is limited at this time.
The relationship between alcohol intake and prognosis in RA is not well understood. Most published studies focus on the relationship between alcohol intake and death, 26 or on the relationship between alcohol intake and the development of RA. 27 Alcohol non-use appears to be associated with the development of RA, at least in one study. 27 Our finding that alcohol non-use is protective against progression is of interest. It is possible that clinician reluctance to use standard methotrexate or leflunomide in patients with higher alcohol intakes explains the poorer prognosis in this group.
Women suffer more autoimmune conditions than men, including RA. 28 Erosive disease occurs more commonly in women, as does sicca syndrome. 28 In men, nodules and rheumatoid lung disease are more common. 28 However, response to treatment is reported to be 30-50% worse in women compared to men for both methotrexate and anti-tumor necrosis factor agents. [28] [29] [30] Others have also reported that men are between two and three times more likely to achieve remission in the early rheumatoid setting, 16,31 reflecting our finding of a two-fold increase in likelihood of achieving remission if the patient is male.
Smoking has previously been shown to be a risk factor for arthritis, interacting with sex by an unknown mechanism. 28 There is also an association between smoking and the presence of CCP antibodies 32, 33 and RF. 34 Several studies have suggested that smoking is a predictor of treatment response. [35] [36] [37] [38] These studies were all of an open-label or observational nature, and the association appears to depend on the treatment studied. More recently, its association as a prognostic factor has been questioned in a randomized, double-blind study. 39 This study reported smoking status not having any impact on treatment responses in patients with early arthritis who were receiving methotrexate therapy. The lack of association in early arthritis reported by Maska and colleagues 39 may be hampered by misclassification issues, a potential issue in real-world data collection studies.
For patients with early RA, current Australian treatment guidelines recommend treatment with simple analgesics, fatty acids, NSAIDs, DMARDs or corticosteroids. 40 DMARDs and low-dose corticosteroids are considered when there are several swollen joints, especially in the presence of RF or anti-CCP. 40 Treatment with a biologic agent is recommended when patients fail to achieve clinical remission with synthetic DMARDS. 41 However, given the finding that patients are not achieving remission within 12-24 months, this suggests that either: (i) the prognostic factors are not adequately predicting those who require more aggressive therapy; (ii) that patients are not having treatment intensified early enough in their disease course; or (iii) patients have treatment-resistant disease.
Importantly, the prognostic factors associated with poor response may reflect the shifting ground as RA therapy advances and intensifies.
Our study has some limitations. Given the realistic clinical setting in which the data were collected; there was a large proportion of missing data for some baseline predictors. Despite this, we believe there is value in the real-world, observational data that was collected and entered by the clinician at the time of consultation, including blood parameters for various predictive factors imported directly from the laboratory, ensuring excellent data capture.
Importantly, the prognostic factors associated with poor response may reflect the shifting ground as RA therapy advances and intensifies. Traditional prognostic factors may have a role in this new group of intensively treated patients, with new prognostic factors requiring consideration as the treatment paradigm evolves.
CONCLUSION
In this observational study, patients with early RA who may benefit from early aggressive therapy include those with high disease activity at baseline, women, those who drink alcohol and those with higher body weight.
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